Interaxon

Interaxon in its US$9.5 million Series C financing round

Client

Interaxon

Value

US$9.5 million

Service

Emerging and High Growth Companies

Date Closed

August 2022

Industry

Pharmaceuticals, Biotech & Life Sciences

Lead Office

Toronto

 

On August 11, 2022, Interaxon announced it had closed its US$9.5 million Series C financing round led by BDC Capital, Alabaster and Export Development Canada with participation from Phyto Partners, Iter Investments, Intretech(HK) Co, and The Clavis Foundation. With this financing round, Interaxon will improve its brain health platform by launching an integrated wellness membership model as well as continue to further research and validate an industry-first feature that tracks longitudinal changes in the brain.

Interaxon is a late-stage venture company in the neurotechnology space.

Osler, Hoskin & Harcourt LLP advised Interaxon with a team consisting of David Jamieson, Chad Bayne, Calvin Leung and Yulia Yugay (Emerging and High Growth Companies).